Aurora kinases in current clinical trials
| Agent | Targets | ClinicalTrials.gov identifier | Sponsor | Patient population |
|---|---|---|---|---|
| MK0457 | Pan Aurora kinase inhibition | NCT00099346 | Merck & Co. | Advanced cancer |
| Pan Aurora kinase inhibition | NCT00104351 | Merck & Co. | Advanced cancer | |
| FLT3 inhibition | NCT00104351 | Merck & Co. | Relapsed or refractory leukemia | |
| Pan Aurora kinase inhibition | NCT00290550 | Merck & Co. | Advanced non-small cell lung cancer | |
| MLN8054 | Aurora-A inhibition | NCT00249301 | Millennium Pharmaceuticals | Advanced solid tumors |
| AZD1152 | Aurora-B inhibition | NCT00338182 | AstraZeneca | Advanced solid tumors |
| PHA-739358 | Pan Aurora kinase inhibition | NCT00335868 | Nerviano Medical Sciences | Relapsed chronic myelogenous leukemia |